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Background: Among the currently available osteoporosis therapeutics, bisphosphonates and 
denosumab are widely used. However, it remains uncertain which therapy is more effective.  
Objective: To determine whether the use of denosumab increases bone mineral density 
(BMD) and reduces the risk of fractures more than bisphosphonates in patients with low 
BMD or osteoporosis. 
Data Sources: We searched PubMed, Embase and the Cochrane Library through Nov  2018.  
Study Selection: Head-to-head randomized controlled trials comparing denosumab versus 
bisphosphonates among adult patients with low BMD or osteoporosis.  
Data Extraction and Synthesis: Random-effects models were used. We identified 10 
eligible trials including 5361 participants. Denosumab increased BMD more than 
bisphosphonate at 12 months, with a mean difference of 1.42% (95% CI 0.95-1.89%, 
p<0.001) at lumbar spine, 1.11% (95% CI 0.91-1.30%; p<0.001) at total hip, and 1.00% 
(95% CI 0.78-1.22%, p<0.001) at femoral neck. At 24 months, the increase difference was 
1.74% (95% CI 1.05-2.43%, p<0.001) at lumbar spine, 1.22% (95% CI 0.66-1.77%, p<0.001) 
at total hip, and 1.19% (95% CI 0.65-1.72%, p<0.001) at femoral neck. There was no 
difference in fracture endpoint at 12 months, but denosumab had a lower osteoporotic 
fracture incidence than alendronate at 24 months (RR 0.51, 95% CI 0.27-0.97).  
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Conclusions: Denosumab improved BMD significantly more than bisphosphonates at the 
lumbar spine, total hip and femoral neck at 12 and 24 months. There was only one study 
demonstrating greater osteoporotic fracture reduction using denosumab. Future longitudinal 
studies with longer follow-up and large sample size are needed to confirm the efficacy 
difference. 
This is a meta-analysis of 10 head-to-head trials comparing of the efficacy of denosumab versus 
bisphosphonates in patients with low bone mineral density or osteoporosis. . 
INTRODUCTION 
Osteoporosis is a chronic, progressive skeletal condition characterized by decreased bone 
mass and microarchitectural deterioration, leading to increased risk of fracture(1). It is 
estimated that more than 9.9 million Americans have osteoporosis and an additional 43.1 
million have low bone mineral density (BMD) (2). The annual direct costs of osteoporosis are 
estimated to reach $25.3 billion by 2025(3).  
Among the currently available osteoporosis therapeutics, bisphosphonates and 
denosumab are the most widely used(1,4). Bisphosphonates are the most prescribed anti-
resorptive agents, which selectively adhere to and remain within bone.  When internalized 
from the bone surface, bisphosphonates inactivate or promote apoptosis of osteoclasts(5). On 
the other hand, denosumab is a fully human monoclonal IgG2 antibody that binds to the 
receptor activator of nuclear factor-κB ligand (RANKL) with high specificity and affinity. 
Denosumab impairs the development, activation, and survival of osteoclasts, thus inhibiting 
bone resorption(6). Due to their different mechanisms of action, bisphosphonates typically 
provide persistent antiresorptive effect after discontinuation, while the effect of denosumab 
on bone turnover are quickly reversible with discontinuation, leading to a transient rebound 
phenomenon(7). Previous phase III clinical trials found both drugs increased BMD and 
reduced the risk of fracture compared to placebo(8–12). However, the relative efficacy of 
bisphosphonates or denosumab remain uncertain (13,14).  
Five meta-analyses have compared denosumab and bisphosphonates in osteoporosis (13–17) 
and while current evidence suggests denosumab might increase BMD and reduce fracture 
risk more than bisphosphonates, these results are not conclusive. Two of these studies 
adopted a network meta-analysis design and reported the indirect treatment comparison of 
denosumab and bisphosphonates(14,16). The other three meta-analyses included only head-to-
head trials(13,15,17) and gave results of direct comparisons. However, several key issues remain 
unresolved. First, results from indirect comparison and direct comparison are 
inconsistent(16,17), which deserves further clarification. Second, the efficacy comparison of 
BMD increase and fracture risk reduction were not well reported at 24 months. Third, current 
direct comparison meta-analyses did not include all key studies and requires an update(15,17). 
Since 2014, five more pivotal head-to-head trials have been published. We performed a direct 
comparison of denosumab and bisphosphonate efficacy, incorporating these recent studies.  
This meta-analysis of head-to-head randomized control trials (RCTs) aims to determine 
whether denosumab is more effective than bisphosphonates in increasing bone mass and 
reducing fracture risk in patients with low bone mineral density or osteoporosis.   
MATERIALS AND METHODS 
The current meta-analysis was conducted in accordance with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines(18,19). This study did not 
require ethical approval as there was no human or animal experiment. 
Study inclusion and exclusion criteria  
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Studies included in this meta-analysis were required to meet the following inclusion criteria: 
(1) study design: RCT with a duration of at least 12 months; (2) study subjects: adult patients 
diagnosed with osteoporosis (T-score at or below −2.5) or low bone mineral density (T-score 
between −1.0 and −2.5) receiving the study intervention(1); (3) study intervention: denosumab 
60 mg subcutaneously every 6 months for at least 12 months (intervention group), or 
bisphosphonate treatment (comparator group), including alendronate (35 or 70 mg once 
weekly), ibandronate (150 mg once monthly), risedronate (150 mg once monthly)  or 
zoledronic acid (5 mg infusion once yearly); and (4) the outcome measurement included the 
mean percentage change in BMD measured by dual-energy X-ray absorptiometry (DXA) of 
lumbar spine, total hip or femoral neck. Trials were excluded if (1) the study population 
included cancer patients or glucocorticoid-induced osteoporosis patients; (2) the same RCT 
was re-analyzed (i.e. we only included the most complete data of each trial once); (3) subjects 
were not randomly allocated to treatments; and (4) studies published as abstracts, reviews 
articles, editorials and letters.  
Information sources and search strategy 
We systematically searched PubMed, Embase and the Cochrane Library from Jan 1, 1980 
until November 8, 2018 with no language restrictions. Additionally, relevant studies were 
obtained by searching references of articles identified in the initial searches, relevant meta-
analyses and systematic reviews. The literature search was performed independently by two 
authors (HL, BJ). Search strategies were developed using text words as well as medical 
subject headings (MeSH) associated with terms relevant to “osteoporosis”, “denosumab”, 
“bisphosphonate” together with “randomized controlled trial”. The full search strategies used 
in PubMed, Embase and Cochrane Library are provided here.(20)  
Study selection  
Our search records were imported into ENDNOTE X8 reference management software 
(Clarivate Analytics, Philadelphia, PA), and two authors (HL, BJ) independently reviewed 
the titles and abstracts of the literature searches. Trials that did not meet the eligibility criteria 
were excluded. After excluding the duplicated and irrelevant articles, the full text of the 
remaining studies was reviewed to ascertain whether they should be included by the 
eligibility criteria. After completion, both authors met and reviewed their selections for 
agreement. Any disagreements were resolved by discussion or by seeking an independent 
third author (CX). 
Data collection process 
The available information and outcomes of all the eligible studies were independently 
extracted by two researchers (HL, BJ). The retained data included study characteristics, 
participant characteristics, type of intervention (type, dose, duration). If data was presented in 
figures, the GetData software was used to extract data from the figures (http://getdata-graph-
digitizer.com/index.php). Mean and SD/standard error/confidence interval (CI) of percentage 
changes of BMD were extracted for calculation. Disagreements were resolved through 
discussion.  
Outcomes 
The primary outcomes were the mean percentage change in BMD (%) at lumbar spine, total 
hip and femoral neck at 12 months. The secondary outcomes were: (1) mean percentage 
change in BMD (%) at lumbar spine, total hip and femoral neck at 24 months; (2) overall 
incidence of vertebral fractures and overall incidence of non-vertebral fractures at 12 and 24 
months; (2) total adverse events, severe adverse events and selected adverse events of interest 
(severe infection, malignancy, death, adverse events leading to withdrawal, gastrointestinal 
disorders and eczema) at 12 months. 
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Subgroup and sensitivity analyses 
Both a priori specified and exploratory subgroup analyses were performed to examine 
potential sources of heterogeneity and explore the reasons of inconsistent results between 
indirect and direct meta-analysis. First, a priori specified subgroup analysis was performed by 
grouping studies into those including alendronate vs. those including any other 
bisphosphonates. Second, exploratory subgroup analysis was performed by grouping studies 
into those including patients who previously received bisphosphonate therapy vs. those 
including patients who did not receive bisphosphonate therapy. And third, we exploratorily 
assessed the route of bisphosphonate administration (oral vs. intravenous). Two additional 
sensitivity analyses for the primary outcomes were performed to examine the heterogeneity 
(1) by omitting 2 small sample size trials from the overall analysis and (2) by omitting 5 trials 
in osteopenic populations.  
Risk of bias assessment 
Two authors (HL, BJ) independently assessed the risk of bias using the Cochrane risk-of-bias 
tool(21). This tool assessed bias across the following seven domains: (1) random-sequence 
generation; (2) allocation concealment; (3) blinding of participants and personnel; (4) 
blinding of outcome assessment; (5) incomplete outcome data; (6) selective reporting; and (7) 
other bias. Each domain was determined as ‘low risk’, ‘unclear risk’ or ‘high risk’. For the 
first four domains, if the trial clearly reported adequate methods, it was regarded as a low risk 
of bias. However, if the trial did not clearly report the methods, it was regarded as an unclear 
risk of bias; if the trial inadequately reported methods, it was regarded as a high risk of bias. 
For incomplete outcome data, we considered ≥20% loss to follow-up to represent a high risk 
of bias. For the selective reporting, we assessed it by comparing each publication with its 
corresponding published protocol, when available. For other sources of bias, we considered 
major imbalances in key baseline characteristics to represent a high risk of bias. Any 
disagreements were resolved through discussion, adjudicated by another reviewer (CX) if 
necessary. 
Statistical analysis 
We used random effects model to calculate pooled estimates, as heterogeneity was 
anticipated(22). For continuous variables (percentage changes in BMD), weighted mean 
difference and 95% CIs were calculated. For dichotomous variables (fracture and adverse 
events), risk ratio (RR) and 95% CIs were calculated. To assess the heterogeneity of the results from 
individual studies, Cochran’s Q statistic, the I² statistic (I² >50% was regarded as substantial heterogeneity) and P values (P 
<0.10 was considered as substantial heterogeneity) were used(23). The preplanned subgroup and sensitivity 
analyses were performed to examine the sources of heterogeneity. Publication bias was 
assessed visually with a funnel plot and Egger’s weighted regression statistic with a P value 
<0.05 indicating significant publication bias. The meta-analysis was analyzed using the 
statistical environment R-3.4.3 (https://cran.r-project.org) with the “meta” and “metafor” 
packages(24). All the tests were two-tailed and a P value of <0.05 was deemed statistically 
significant. 
RESULTS 
Search results 
A total of 523 articles were obtained through electronic and manual searches. After 55 
duplicates were removed, the titles and abstracts of 468 records were reviewed. Of the 468 
records reviewed, 433 records were excluded for not meeting the inclusion criteria, and thus 
the remaining 35 articles were retrieved for further assessment. Twenty-five trials were 
excluded for not being head-to-head trials or follow-up reports of same trial. Ten trials(9,25–31) 
fulfilled criteria and were included in the meta-analysis (Figure 1). 
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Characteristics of included trials 
The main characteristics of the included trials were summarized in Table 1. These trials were 
published from 2006 to 2018 and involved a total of 5361 patients, with the sample size 
ranging from 64 to 1189. Mean age ranged from 63 to 78 and 99.0% were females. One 
thousand five hundred and thirty-three patients (28.6%; 3 studies) had no prior osteoporosis 
treatment, 714 patients (13.3%; 1 study) had previous fractures, 2914 patients (54.3%, 5 
studies) received bisphosphonate treatment before the study and 200 patients (3.7%, 1 study) 
received teriparatide before the study. The bisphosphonates included alendronate, 
ibandronate, risedronate and zoledronic acid. The doses of bisphosphonates were equivalent 
to alendronate 70 mg once weekly for oral bisphosphonate and 5 mg infusion once yearly 
zoledronic acid for intravenous bisphosphonate, except one study which used 35 mg once 
weekly alendronate (9.4%, 242 of 2562) (28), the study duration was 12 months for 8 trials and 
24 months for 2 trial. Six of the ten studies compared the efficacy of denosumab and 
alendronate, 2 studies zoledronic acid, and 1 study ibandronate and risedronate. All studies 
reported concomitant administration of daily oral calcium and vitamin D supplements. 
Risk of bias assessment 
Risk of bias was assessed with the Cochrane risk-of-bias tool(32). Two trials did not clearly 
report the random sequence generation(29,31). Three trials (28–30)did not clearly report the 
allocation concealment. Five trials used an open-label design(27,29,30,33,34). Blinding of 
outcome assessment was inadequately reported in only 3 trials(27,30,33). There was a low risk 
of attrition bias, reporting bias, and other biases in all trials except for one that had a high risk 
of selective reporting(30). Two studies had a relatively small sample size (64 and 94) (9,30). 
Primary analysis: mean percentage change in BMD at lumbar spine, total hip and femoral neck 
at 12 months 
The primary analysis involved ten trials with a total of 5254 patients. Compared to 
bisphosphonates, the incremental 12-month increase in BMD with denosumab was greater by 
1.42% (95% CI 0.95%-1.89%, p<0.001) at lumbar spine, 1.11% (95% CI 0.91%-1.30%; 
p<0.001) at total hip, and 1.00% (95% CI 0.78%-1.22%, p<0.0001) at femoral neck (Figure 
2). Cumulative meta-analysis(35) showed that more BMD improvement with denosumab 
became evident in 2010, when 1769 patients had been randomized. At the end of 2010, the 
mean difference in BMD improvement was 1.05% (95% CI 0.66%-1.44%) at lumbar spine, 
0.92% (95% CI 0.70%-1.15%) at total hip and 0.68% (95% CI 0.34%-1.01%) at femoral 
neck. Subsequent trials brought the number of patients to 5254, resulting in a slightly higher 
point estimate at the above 3 sites.  
Sensitivity analyses 
After removing five studies in osteopenic population, the mean BMD increase difference was 
1.47% (95%CI, 0.97% to 1.96%) at lumbar spine, 1.04% (95%CI, 0.85% to 1.12%) at total 
hip and 0.97% (95%CI, 0.73% to 1.15%) at femoral neck. After removing the two small 
trials(9,30), the mean difference increased from 1.42% (95% CI 0.95%-1.89%, p<0.001) to 
1.62% (95%CI, 1.14% to 2.09%) at lumbar spine(36). In addition, mean difference at total hip 
and femoral neck also increased. After excluding one study including 5% men(28),  results 
were consistent with the primary analysis.  
Subgroup analysis 
Subgroup analyses were performed based on the specific bisphosphonate and pretreatment 
status. The results showed that denosumab improved BMD more than each of the three oral 
bisphosphonates (alendronate, ibandronate and risedronate) at lumbar spine, total hip and 
femoral neck. However, compared to zoledronic acid, denosumab only showed significant 
superiority in total hip and femoral neck BMD improvement(37). 
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Subgroup analysis stratified by prior treatment status: (previously treated with 
bisphosphonate or not). In patients who did not previously receive bisphosphonate treatment, 
denosumab increases lumbar spine BMD more than bisphosphonates (mean difference, 
0.83%; 95% CI 0.27% to 1.39%; p<0.001). In patients who received previous bisphosphonate 
treatment, denosumab still resulted in greater lumbar spine BMD improvement than 
bisphosphonates (mean difference, 1.75%; 95% CI, 1.28% to 2.23%; p<0.001). There was a 
significant interaction between the subgroups of different bisphosphonate pretreatment status 
in lumbar spine BMD improvement (previously treated with bisphosphonates 1.75% vs. 
previously not treated 0.83%, p for interaction=0.014). Similar results were found at total hip 
(previously bisphosphonates treated 1.22% vs. previously not treated 0.93%, p for 
interaction=0.089) and femoral neck (previously bisphosphonates treated 1.20% vs. 
previously not treated 0.83%, p for interaction=0.069), but subgroup difference was not 
significant (Figure 3).   
Another subgroup analyses were performed based on alendronate or non-alendronate 
bisphosphonates. The BMD increase difference was 1.91% (95% CI 1.36%-2.47%, p<0.001) 
at lumbar spine for alendronate trials and 1.11% (95% CI 0.63%-1.58%, p<0.001) for non-
alendronate bisphosphonate at 12 months, p-value for subgroup difference was 0.031. Similar 
results could also be seen at two other areas, total hip (subgroup difference p=0.004) and 
femoral neck (subgroup difference p=0.040)(38).  
Subgroup analyses indicated that heterogeneity can be assumed due to two small sample 
studies (Q=5.37, p=0.021) and the difference in the population characteristics, such as 
different types of bisphosphonate and pretreatment status. 
Secondary outcomes 
Two trials (795 patients) reported changes in BMD at 24 months. The pooled results showed 
at 24 months, BMD increase difference between denosumab and bisphosphonate was 1.74% 
at spine, 1.22% at total hip, and 1.19% at femoral neck, which was slightly higher than the 12 
month BMD increase difference (Figure 4).  
Five trials(25,26,29,31,34) (3540 patients) reported fracture data at 12 months and one trial(28) 
(714 patients) reported fracture data at 24 months. Due to the sparse report of vertebral 
fractures and non-vertebral fractures, we reported the pooled fracture endpoints, the incidence 
of any fractures and osteoporotic fractures. Denosumab therapy did not demonstrate 
significant difference in reducing the risk of any type of fracture (RR 1.32, 95% CI 0.93-
1.87) nor osteoporotic fracture (RR 0.92, 95% CI 0.39-2.15) at 12 months (Figure 5). 
Denosumab therapy showed no significant difference in reducing the risk of any type of 
fracture (RR 0.81, 95%CI 0.47 to 1.41) at 24 month. However, regarding osteoporotic 
fracture, denosumab showed better performance than alendronate with RR 0.51 (95%CI 0.27 
to 0.97) (Figure 5).   
Six trials(25–27,29,31,33) with 4242 patients reported adverse events and severe adverse 
events at 12 months. Denosumab therapy did not demonstrate a higher adverse events risk 
(RR 0.99, 95% CI 0.95-1.03) nor severe adverse events risk (RR 1.02, 95% CI 0.79-1.31) 
than bisphosphonates therapy (Figure 6). Risk of selected adverse events of interest, 
including severe infection (RR 1.05, 95% CI 0.61-1.80), malignancy (RR 0.99, 95% CI 0.66-
1.50), death (RR 0.66, 95% CI 0.16-2.63), adverse events leading to withdrawal (RR 0.62, 
95% CI 0.38-1.03), gastrointestinal disorders (RR 0.99, 95% CI 0.75-1.31) and eczema (RR 
2.01, 95% CI 0.63-6.42) were also similar for denosumab and bisphosphonates(39).  
Publication bias 
The publication bias of the primary outcomes was assessed using visual examination of 
funnel plots (40) and Egger’s weighted regression statistic (p=0.671, p=0.863 and p=0.514 for 
three primary outcomes respectively, mean difference of BMD change at lumbar spine, total 
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hip and femoral neck) indicated no significant publication bias. Trim-and-Fill results 
suggested only zero to three missing studies were needed to achieve a symmetrical funnel 
plot.  
DISCUSSION 
Main findings 
This meta-analysis of head-to-head trials gave evidence of direct comparison between 
denosumab and bisphosphonates. Our study provides moderately strong evidence(41) that 
denosumab is more effective in increasing BMD at lumbar spine, total hip and femoral neck 
than bisphosphonates at 12 and 24 months. However, fracture risk reductions were similar at 
12 months. Only one study reported denosumab to have lower osteoporotic fracture incidence 
than alendronate at 24 months. Safety profiles between denosumab and bisphosphonates were 
similar. 
Clinical meaning 
The association between anti-resorptive agents related BMD increase and fracture risk 
reduction is very important for osteoporosis treatment initiation and monitoring. In our study, 
the difference in the 12-month BMD increase between denosumab and bisphosphonate was 
1.42% at spine, 1.11% at total hip and 1.00% at femoral neck. Although these numbers 
appear small, such differences would translate into clinically important fracture differences if 
observed in large enough populations. BMD change, especially hip BMD change, is the most 
important surrogate for evaluation of therapeutic response(42). According to a recent meta-
analysis using individual patient data from 21 randomized, placebo-controlled osteoporosis 
trials of > 83,395 subjects showed changes in total hip and femoral neck BMD over two years 
explained 60%-65% of the treatment-related reduction in fracture risk(42). More specifically, 
for patients who received anti-resorptive agents, treatment-related 6% increase of lumbar 
spine BMD at 1 year was associated with 39% reduction in nonvertebral fracture risk, and 
3% increase of hip BMD was associated with 46% reduction in nonvertebral fracture risk(43). 
In our study, denosumab and bisphosphonate had different BMD increase profiles. A 
difference of 1.42% at the lumbar spine may not be associated with clinically significant 
reduction in fracture risk. However,  a difference of 1.11% at total hip BMD and  an 
difference of 1.00% at femoral neck would be expected to yield 15%-21% fracture risk 
reduction difference at 12 months, and larger number are expected for longer treatment 
duration (24 months or more).  
Comparison with previous studies 
Previous indirect comparison, or network meta-analysis by Mandema et al showed that 
denosumab resulted in greater BMD improvement in lumbar spine and total hip from 12 
months to 36 months when compared to alendronate and zoledronic acid(16). The point 
estimates of spine BMD improvement difference for denosumab was only 0.4% greater than 
zoledronic acid, 0.8% greater than alendronate at 12 months. Recent head-to-head meta-
analysis by Wu et al reported a pooled estimate of BMD improvement difference 1.55% at 
lumbar spine, 1.05% at total hip and 1.06% at femoral neck(17). In our study, we included 
three more studies and excluded two studies from the same trial, the point estimates of the 
BMD improvement difference were similar to Wu’s study, 1.31% at lumbar spine, 1.11% at 
total hip and 1.01% at femoral neck. But the inconsistent results between indirect and direct 
meta-analysis deserve a further clarification. Here we propose a possible explanation from 
the aspect of denosumab and bisphosphonates mechanisms.  
Denosumab increase BMD progressively as long as the treatment is continued(44). On the 
other hand, bisphosphonates have persistent but not progressive antiresorptive effect; 
bisphosphonates increase BMD over the first few years but then plateaus(35). When 
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comparing the effect of denosumab and bisphosphonates, prior treatment with 
bisphosphonates will attenuate the efficacy of subsequent bisphosphonates. This phenomenon 
may potentially inflate the efficacy difference between denosumab and bisphosphonates as 
noted in our exploratory subgroup analysis performed by grouping patients with and without 
prior bisphosphonate therapy. In our current meta-analysis, the point estimates of BMD 
improvement difference in treatment naïve patients was 0.83% at spine, 0.93% at total hip 
and 0.83% at femoral neck, which may reflect the true efficacy difference.  
In previously bisphosphonate-treated patients, the difference was 1.75% at spine, 1.22% 
at total hip and 1.20% at femoral neck. The larger efficacy difference in the latter subgroup 
may help us make clinical decisions regarding the sequential use of osteoporosis medication. 
In clinical practice, the most commonly used anti-osteoporosis medication are 
bisphosphonates.  When the first bisphosphonate is ineffective (e.g., due to unsatisfactory 
response or fractures), a different medication should be considered. Results of this study 
suggest that in patients treated with a prior bisphosphonate switching to denosumab would 
result in greater increase of BMD than to another bisphosphonate.  
Current evidence on the difference in fracture risk reduction between denosumab and 
bisphosphonates is still limited.  A previous network meta-analysis(14) reported that 
denosumab was more effective than bisphosphonates in preventing new vertebral fractures 
(RR 0.62; 95%CI 0.44 to 0.87), but not in preventing non-vertebral fracture, hip fracture or 
wrist fracture. Only one trial reported that denosumab was more effective in preventing 
osteoporotic fractures than alendronate at 24 months (RR 0.51, 95%CI 0.27 to 0.97)(28). A 
recent observational data analysis showed denosumab was associated with a 23% lower risk 
of vertebral fracture than alendronate (HR 0.77, 95%CI 0.57 to 1.03)(45). There was only one 
study demonstrating greater osteoporotic fracture reduction using denosumab. However, 
future longitudinal studies with longer follow-up and large sample size are needed to confirm 
the efficacy difference. 
Safety profile did not show significant difference between denosumab and 
bisphosphonates at 12 months. Denosumab does not demonstrate a higher adverse AEs or 
SAEs than bisphosphonates. 
Strengths and limitations 
Although several meta-analyses on this topic were published previously, our study has 
several distinct strengths. First, we incorporated BMD and fracture data at 24 months, and 
demonstrated better performance using denosumab in reducing osteoporotic fracture at 24 
months. Previous published meta-analysis either missed key studies (the study with fracture 
as endpoint for 2 years and recently published trials) or only focused on 12-month data.  
Second, all prior meta-analyses overlooked important profiles of the study population, and 
important subgroup analysis were not performed(15–17),  especially prior bisphosphonate 
treatment status. Our study demonstrated the efficacy difference between denosumab and 
bisphosphonates in prior bisphosphonate treated patients relative to treatment naïve patients. 
This result suggested that if the prior use of bisphosphonate was ineffective, switching to 
denosumab would improve BMD more than switching to another bisphosphonate. However, 
several limitations should also be noted: (1) There were some methodological limitations in 
some of the included trials, such as the inadequate concealment of treatment allocation. (2) 
The quality of evidence for reduced incidence of fracture was only moderate, and only one 
study reported fracture endpoints at 24 months. (3) There was significant heterogeneity in 
some outcomes due to the various types of bisphosphonates and patient characteristics. Given 
these limitations, results of this meta-analysis should be interpreted cautiously. 
Implications for future studies 
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Several knowledge gaps remain regarding the comparative effectiveness of denosumab and 
bisphosphonates. First, evidence on long-term BMD benefit of denosumab compared to 
bisphosphonates was very limited. Second, only one study reported the efficacy difference on 
fracture endpoint between denosumab and bisphosphonates at 2 years; more studies are 
needed to clarify the fracture risk reduction benefit of denosumab compared to 
bisphosphonate. Third, whether there would be a response difference to treatment with 
denosumab between patients previously treated with bisphosphonates and treatment naïve 
patients also remains unclear. Future studies are needed to fill the above knowledge gaps. 
Conclusions 
Denosumab significantly improved the BMD at lumbar spine, total hip and femoral neck 
more than bisphosphonates at 12 and 24 months. There was only one study demonstrating 
greater osteoporotic fracture reduction using denosumab at 24 months.  The better 
performance of denosumab over bisphosphonates in increasing BMD were found in both 
treatment-naïve patients and previously bisphosphonate treated patients.  
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Figure 1 Flow diagram shows the process of literature selection. 
Figure 2 Forest plot for the mean difference of BMD changes (%) at lumbar spine, total hip 
and femoral neck at 12 months. 
Figure 3 Forest plot of the BMD changes at three sites at 12 months (subgroup analysis 
stratified by previous treatment status) at lumbar spine (a), total hip (b) and femoral neck (c). 
Figure 4 Forest plot for the mean difference of BMD changes (%) at lumbar spine, total hip 
and femoral neck at 24 months. 
Figure 5 Forest plot of any fracture and osteoporotic fractures at 12 and 24 months. 
Denosumab therapy did not demonstrate significant difference in reducing the risk of any 
type of fracture (a), osteoporotic fracture (b) at 12 months nor the risk of any type of fracture 
at 24 months (c), but denosumab had lower osteoporotic fracture than bisphosphonate (d). 
Figure 6 Forest plot of adverse events at 12 months. Risk ratio of any adverse events (a) and  
severe adverse events (b). 
Table 1. Characteristics randomized controlled trials among osteoporosis patients comparing 
denosumab to bisphosphonates 
Included 
Trials 
Treatment 
status 
Basic 
therap
y* 
Bisphospho
nate type 
Denosumab group (60 
mg ⁄ 6 mo) Bisphosphonate group 
Durati
on 
(mo) N 
Ag
e 
(S
D) 
BM
D 
TH 
(SD
)# 
BM
D 
LS 
(SD
) # 
N 
Age 
(SD
) 
BM
D 
TH 
(SD
) # 
BM
D 
LS 
(SD
) # 
Dose 
McClung et al, 
2006 (United 
States) 
Untreated 
1000 
mg Ca, 
400 IU 
Vit D 
Alendronate 47 
63.
1 
(8.
1) 
-1.4 
(0.8) 
-2.2 
(0.7
) 
47 
62.8 
(8.2
) 
-2.0 
(0.9
) 
-2.0 
(0.9
) 
70 mg 
once 
weekl
y for 
12 mo 
12 
Kendler et al, 
2010 
(International) 
Bisphospho
nate treated 
1000 
mg Ca, 
400 IU 
Vit D  
Alendronate 253 
66.
9 
(7.
8) 
-1.8 
(0.8
2) 
-2.6 
(0.7
5) 
25
1 
68.2 
(7.7
) 
-1.8 
(0.7
) 
-2.6 
(0.8
) 
70 mg 
once 
weekl
y for 
12 mo 
12 
Brown et al, 
2009 
(International) 
Untreated 
500 mg 
Ca, 
400 or 
800 IU 
Vit D  
Alendronate 594 
64.
1 
(8.
6) 
-1.8 
(0.8) 
-2.6 
(0.8
) 
59
5 
64.6 
(8.3
) 
−1.7 
(0.8
) 
−2.6 
(0.8
) 
70 mg 
once 
weekl
y for 
12 mo 
12 
Recknor et al, 
2013 
(International) 
Bisphospho
nate treated 
At 
least 
500 mg 
Ca, 80
0 IU 
Vit D 
Ibandronate 417 
67.
2 
(8.
1) 
-1.8 
(0.7) 
-2.5 
(0.9
) 
41
6 
66.2 
(7.8
) 
-1.8 
(0.7
) 
-2.5 
(0.8
) 
150 
mg 
once 
month
ly for 
12 mo 
12 
Nakamura et 
al, 2014 
(Japan)$ 
Previous 
fractures 
600 mg 
or 
more 
Ca, 40
0 IU 
Vit D  
Alendronate 472 
69.
9 
(7.
4) 
-2.0 
(0.8) 
-2.8 
(0.9
) 
24
2 
70.2 
(7.3
) 
-2.0 
(0.8
) 
-2.7 
(0.9
) 
35 mg 
once 
weekl
y for 
24 mo 
24 
Roux et al, 
2014 
(International) 
Bisphospho
nate treated 
At 
least 
1000 
mg Ca, 
800 IU 
Risedronate 435 
67.
8 
(7.
0) 
−1.6 
(0.9) 
−2.2 
(1.2
) 
43
5 
67.7 
(6.8
) 
−1.9 
(0.7
) 
−2.3 
(1.1
) 
150 
mg 
once 
month
ly for 
12 
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Vit D 12 mo 
Anastasilakis 
et al, 2015 
(Greece) 
Bisphospho
nate treated 
1000 
mg Ca, 
800 IU 
Vit D 
Zoledronic 
acid 34 
63.
2 
(9.
6) 
- 
-1.9 
(1.3
) 
30 
63.3 
(10.
1) 
- 
-
2.18 
(0.9
) 
5 mg 
infusi
on 
once 
yearly 
for 12 
mo 
12 
Miller et al, 
2016 
(International) 
Bisphospho
nate treated 
At 
least 
1000 
mg Ca, 
At 
least 
800 IU 
Vit D  
Zoledronic 
acid 
32
1 
68.
5 
(7.
1) 
 -1.9 
(0.7)  
-2.7 
(0.8
) 
32
2 
69.5 
(7.7
) 
-1.9 
(0.8
)  
-2.6 
(0.9
) 
5 mg 
infusi
on 
once 
yearly 
for 12 
mo 
12 
Kendler et al, 
2011(Internati
onal) 
Untreated 
1000 
mg Ca, 
at least 
400 IU 
Vit D 
Alendronate 126 
65.
1 
(7.
6) 
-
1.60 
(0.7
4) 
-
2.04 
(1.1
6) 
12
4 
65.3 
(7.7
) 
-
1.60 
(0.7
6) 
-
1.89 
(1.1
3) 
70 mg 
once 
weekl
y for 
12 mo 
12 
Niimi et al, 
2018 (Japan) $ 
Teriparatide 
treated 
Active 
or 
native 
Vit D 
in 
DMAb 
arm 
Alendronate 100 
78.
0 
(8.
0) 
- 
-1.7 
(1.6
) 
10
0 
78.0 
(9.0
) 
- 
-1.7 
(1.2
) 
35 mg 
once 
weekl
y for 
12 mo 
12 
* The doses in basic therapy were given daily, Ca, calcium; Vit D, vitamin D; IU, international unit. 
# BMD, Bone mineral density,  T-Score were used. TH, total hip; LS, lumbar spine. Mo: months.  
$ Nakamura et al’s study included both 95% women and 5% men, and Niimi et al’s study included 90% women 
and 10% men, we used the data of the whole population. 
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